eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc. (Nasdaq: LWAC) is a clinical-stage biopharmaceutical company focused on translation regulation therapeutics in oncology, which reached public markets through a de-SPAC business combination with Locust Walk Acquisition Corp., a healthcare-focused blank check company sponsored by Locust Walk Partners. Locust Walk Acquisition Corp. priced its IPO in 2021 targeting the life sciences sector. As a post-merger public company, eFFECTOR filed an 8-K current report with the SEC on June 14, 2024, under accession number 0001193125-24-161574. Sign up at SpacDesk for the complete filing history, sponsor profile, and deal timeline for LWAC and hundreds of other SPAC transactions.